Tag: IDH-2 mutated

Addition of bevacizumab fails to benefit overall survival in newly diagnosed glioblastoma [RTOG 0825 trial]

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

byDaniel Goldshteinand1 others

August 21, 2023

1. Median progression-free survival was shown to be 27.7 months in the vorasidenib group vs 11.1 months in the placebo ...

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

α-synuclein pathology is associated with faster tau accumulation in women
Higher ultra-processed food intake in young children is associated with adverse early behavioural outcomes
Lower preoperative serum calcium is associated with increased risk of postoperative complications in patients undergoing orthopedic surgery

No Result

View All Result